Agenus. has been granted a patent for antibodies that specifically target and inhibit the function of TIM-3, a protein involved in immune regulation. The patent includes details on the antibodies’ structure, pharmaceutical compositions, and methods for therapeutic use. GlobalData’s report on Agenus gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Agenus, Personalized cancer vaccines was a key innovation area identified from patents. Agenus's grant share as of June 2024 was 33%. Grant share is based on the ratio of number of grants to total number of patents.
Antibodies that antagonize tim-3 function for treatment
The patent US12011481B2 describes an isolated antibody that specifically targets human T-cell immunoglobulin and mucin-domain containing-3 (TIM-3). The claims detail the structural components of the antibody, including the heavy chain variable region (VH) and light chain variable region (VL), which consist of specific complementarity determining regions (CDRs). The VH is defined by CDRH1, CDRH2, and CDRH3, with amino acid sequences selected from SEQ ID NOs: 24, 25, and 26. Similarly, the VL comprises CDRL1, CDRL2, and CDRL3, with sequences from SEQ ID NOs: 37, 39, 40, 41, 44, and 47. The claims further specify variations in the amino acid sequences, including those that maintain at least 95% identity to the specified sequences.
Additionally, the patent outlines the potential constant regions for the antibody, which may include various human immunoglobulin classes such as IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2, along with their variants. Specific mutations and modifications, such as non-fucosylated IgG1 and IgG4 with an S228P mutation, are also included. The claims extend to pharmaceutical compositions containing the isolated antibody and a pharmaceutically acceptable carrier, as well as polypeptides representing the heavy and light chains of the antibody. This patent provides a comprehensive framework for the development of TIM-3 targeting antibodies, which may have therapeutic applications in immunology and oncology.
To know more about GlobalData’s detailed insights on Agenus, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
